Variquel

Quick links to important sections

Variquel

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Variquel

Quick Facts

Property Description
Active ingredient Terlipressin (a nonapeptide prodrug)
Form Solution for Injection or Powder and Solvent
Pharmacological class Vasoconstrictor (specifically, Splanchnic)
Origin Synthetic polypeptide hormone

What Type of Medicine is Variquel?

Variquel is a proprietary medicinal product whose active ingredient is Terlipressin, classified primarily as a vasoconstrictor. This medicine is a synthetic polypeptide hormone specifically engineered to function as a longer-acting analogue of the naturally occurring human hormone, vasopressin. Terlipressin is not a natural compound; rather, it is chemically synthesized to achieve precise control and reliable physiological performance, making it clinically recognized for managing severe circulatory dynamics.


Variquel's Composition and Preparation

The functional component of Variquel is its sole active ingredient, Terlipressin, which is structurally a nonapeptide prodrug. The medicine is a single active ingredient product and is prepared as a sterile preparation for administration via injection. It is supplied either as a ready-to-use solution for injection or as a powder and solvent requiring reconstitution with an aqueous solvent. As a polypeptide, Terlipressin must be delivered directly into the circulation via the intravenous route to ensure its full vasoactive effect is immediate and completely absorbed by the body. This injectable form is a distinguishing feature necessary for its use in acute, time-sensitive settings.


General Purpose of Terlipressin

The fundamental goal of Variquel is to achieve highly selective splanchnic vasoconstriction, which is the targeted tightening of blood vessels supplying the digestive organs. This targeted action is utilized to efficiently reduce high blood pressure within the portal venous system, a critical circulatory network associated with the liver. By focusing its vasoconstrictor effect primarily on this internal circulation, Terlipressin helps stabilize acute conditions involving circulatory imbalances, serving as an essential tool for rapid and controlled management of vessel dynamics. A typical neutral use scenario for a drug in this class involves the need to rapidly reduce pressure in enlarged blood vessels.

What side effects are possible with Variquel?

Possible Side Effects and Safety Information

The official safety profile for Variquel (Terlipressin) is defined by its strong vasoconstrictor action, leading to a spectrum of officially documented adverse reactions classified by frequency and affected organ system. The most frequently observed reactions, classified as Very Common (10%), include abdominal pain, nausea, diarrhea, dyspnea (shortness of breath), and respiratory failure.

Reactions categorized as Common (1%-10%) include bradycardia (slow heart rate), fluid overload, and various ischemia-related events affecting the heart, periphery, or intestines. Serious adverse events, highlighted in regulatory documents, include a prominent risk of fatal respiratory failure and severe ischemic complications. The safety data groups these effects across key System-Organ Classes, such as Respiratory, Cardiac, Vascular, and Gastrointestinal Disorders.

Regulatory documents include specific safety constraints and population notes. Use is generally contraindicated in patients with ongoing coronary, peripheral, or mesenteric ischemia and in those with hypoxia or worsening respiratory symptoms. Additionally, specific caution or avoidance notes apply to patients with ACLF Grade 3 (advanced liver disease), severe cardiovascular conditions, and advanced renal dysfunction, as their documented risks may increase. The onset of certain serious effects, like respiratory failure, may be delayed, with a median onset noted several days into treatment, according to supporting clinical data.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation states that exceeding the recommended dose of Variquel (Terlipressin) carries a dose-dependent risk of severe circulatory adverse effects. This risk forms the basis of the official overdose profile and mandates specific actions.


Documented Overdose Manifestations

Classification Manifestation/Outcome
Cardiovascular Effects Acute hypertensive crisis; Severe bradycardia; Ischemic events (e.g., cardiac, peripheral); Myocardial infarction; Ventricular arrhythmias (including Torsade de pointes).
Fluid/Respiratory Effects Fluid overload with pulmonary oedema; Serious or fatal respiratory failure.

Required Emergency Actions

Regulatory agencies mandate that the recommended dose must not be exceeded. If overdose is suspected or if signs of severe circulatory or respiratory distress appear, immediate medical attention must be sought. Official labeling requires the discontinuation of the medicine if severe symptoms, such as hypoxia or increased respiratory symptoms, occur. No specific antidote is known; therefore, management focuses on symptomatic and supportive treatment.

  • Population Note: The risk of acute hypertensive crisis is heightened for patients with recognized hypertension in an overdose setting. Management may involve using a vasodilator-type alpha-blocker, as described in the Summary of Product Characteristics (SmPC).

Therapeutic Uses of Variquel

Variquel may be used for managing symptoms associated with acute and fluctuating challenges. It is relevant when short-term symptomatic assistance is needed during phases when symptoms become more noticeable and interfere with daily functioning. The medicine is commonly used in clinical contexts involving significant physiological stress, relevant in contexts involving heightened systemic burden, where supportive symptom management is appropriate.


Easing Sudden & Intensifying Discomfort

This block is relevant in contexts marked by increased discomfort or tension, such as situations involving certain distressing symptoms. Variquel helps address symptom clusters that may become intense or disruptive, and may help improve day-to-day comfort during symptomatic periods. The main uses often involve conditions characterized by systemic imbalance and heightened physiological activity, often used across conditions presenting with systemic or localized discomfort.

“Applied across domains where additional symptomatic support is needed.”

Assisting with Temporary Functional Stability

Variquel is applied in clinical settings that involve acute or unstable symptom patterns, which may create noticeable physiological strain. It supports functional well-being and offers symptomatic relief that may help patients cope more steadily with difficult episodes.

Quick Fact: Relief for Physiological Strain


Support for Episodic & Recurrent Symptom Patterns

This medicine is commonly used across conditions presenting with acute episodes and recurrent or episodic manifestations. It is applied across domains where additional symptomatic support is needed, supporting the patient during difficult episodes by easing distress and helps ease the overall symptom burden.

Eligibility and Restrictions for Use

Who Can and Cannot Use Variquel?

Variquel (Terlipressin) is subject to strict population-eligibility rules established by regulatory authorities. The medicine is contraindicated and must not be used in several populations.


Absolute Contraindications

Use is strictly forbidden in pregnant women and in patients with known hypersensitivity to the active substance. The medicine must also be avoided in individuals experiencing hypoxia or rapidly worsening respiratory symptoms, as well as those with ongoing coronary, peripheral, or mesenteric ischemia.


Age and Organ Function Restrictions

Adults (18 years and older) are the approved population. The medicine is not recommended for children and adolescents (under 18 years) because safety and efficacy are not established. Older adults (over 70) require caution due to potential increased sensitivity.

Conditional restrictions apply to organ function. Use is avoided in patients with advanced renal dysfunction (serum creatinine ge 5.0 mg/dL) and severe liver disease (ACLF Grade 3 or MELD ge 39) unless the clinical benefit significantly outweighs the documented risks. Regulatory documents also advise avoiding use in patients with a history of severe cardiovascular or cerebrovascular disease. For nursing mothers, a risk to the child cannot be excluded, requiring a decision to discontinue either breastfeeding or therapy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Variquel's interaction profile is primarily defined by pharmacodynamic effects that influence the cardiovascular system, as documented in official regulatory labeling. There are no documented drug-drug interactions affecting its clearance via common metabolic pathways, such as CYP enzymes, nor are there official restrictions concerning food, alcohol, or herbal products.

Documented Pharmacodynamic Interaction Patterns

The most clinically significant interactions involve additive effects on heart rate and cardiac rhythm, requiring caution with specific medication classes:

  • Bradycardia-Inducing Drugs: Co-administration with medicinal products known to induce bradycardia, such as Propofol or Sufentanil, may cause severe lowering of the heart rate and subsequent reduction in cardiac output.
  • QT-Prolonging Agents: Caution is required with medicines that can prolong the QT interval due to the risk of ventricular arrhythmias. This includes Class IA and III antiarrhythmics, Erythromycin, Tricyclic Antidepressants, and certain Antihistamines.
  • Electrolyte-Altering Drugs: Use with medications that may cause hypokalaemia or hypomagnesemia (such as certain Diuretics) requires careful consideration, as these electrolytic abnormalities can increase the risk of developing arrhythmias.
  • Vascular Effects: Co-administration with non-selective beta-blockers is documented to increase the hypotensive effect of Variquel on the portal venous system.

No specific medicinal product is formally classified as a contraindicated combination with Variquel in regulatory prescribing information.

Mechanism of Action

Variquel is the synthetic prodrug terlipressin acetate, which is enzymatically cleaved by endothelial peptidases to release the active metabolite, lysine vasopressin (lypressin). This conversion process provides a prolonged duration of action compared to the natural hormone.

The active metabolite, lypressin, functions as a vasopressin receptor agonist, primarily targeting the V1 receptors (V1a) located on the smooth muscle cells of the vasculature. Activation of these Gq-protein coupled receptors initiates a cascade that results in an increase of intracellular calcium concentration.

This molecular event triggers the contraction of the vascular smooth muscle, resulting in generalized vasoconstriction. In the splanchnic circulation—which supplies the abdominal organs—this action selectively reduces mesenteric blood flow, leading to a substantial decrease in the portal venous pressure. This modulates system-level hemodynamics by increasing systemic vascular resistance and mean arterial pressure.

Dosage and Administration Information

Variquel is administered exclusively via the intravenous (IV) route as a bolus injection, a method necessary for its polypeptide structure and its requirement for immediate circulation within acute clinical settings. The medicine is typically supplied as a lyophilized powder, which must be reconstituted with 5 mL of 0.9% Sodium Chloride Injection before its use.

The treatment protocol dictates a consistent dosing frequency of every 6 hours (q6h). The regimen begins with a starting dose of 0.85 mg administered on Days 1 through 3. On the fourth day of treatment, the dose is assessed and adjusted based on the patient's change in serum creatinine (SCr) from baseline. If the SCr has decreased by 30% or more, the 0.85 mg dose is continued. If the response is less than 30% improvement, the dose is increased to 1.7 mg every 6 hours. If the SCr remains at or above the baseline level, the medicine should be discontinued.

Each dose must be physically administered as a slow IV bolus injection over 2 minutes. The entire course is limited to a maximum of 14 days. However, treatment may be stopped earlier once the patient achieves a sustained improvement in kidney function, defined as maintaining two consecutive SCr values of 1.5 mg/dL or less for 24 hours. Use is generally restricted to adults, as the safety and efficacy have not been established in pediatric patients. Furthermore, the medicine is not recommended for use in patients presenting with baseline SCr greater than 5 mg/dL.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Variquel

Evidence for use in Hepatorenal Syndrome–Acute Kidney Injury (HRS-AKI)

The main evidence base for Variquel in the context of Hepatorenal Syndrome–Acute Kidney Injury (HRS-AKI) comes from large Randomized Controlled Trials (RCTs) and subsequent meta-analyses. These studies focused on adult patients with advanced liver disease, such as cirrhosis, who experienced a rapid decline in kidney function. The research primarily examined the effect of the medicine compared to a placebo on the functional outcomes of the kidneys.

Clinical trials reported measurements of HRS reversal, defined by a specific measured change in the blood biomarker serum creatinine without the need for kidney replacement therapies. Studies reported patterns regarding the reversal of kidney function decline, but some findings were varied when research explored measurements of overall survival (e.g., at 90 days) compared to placebo groups. This research describes what has been observed—measured kidney function outcomes—and what is still uncertain—a definitive change in long-term survival for all treated patients.


Evidence for use in Acute Bleeding from Esophageal Varices

Research for the use of Variquel in Acute Bleeding from Esophageal Varices also relies heavily on RCTs and systematic reviews. These trials focused on adult patients with cirrhosis experiencing severe, acute bleeding from enlarged veins in the esophagus. The research primarily examined outcomes related to the achievement of initial control over acute bleeding (hemostasis) and outcomes monitored included the rate of rebleeding and the patients’ requirements for blood transfusions.

However, comparative evidence is lacking for certain endpoints, and the frequent use of the medicine with concurrent therapy limits the isolation of the medicine’s single contribution to the overall observed patterns. This research provides context for how the medicine may be used in observational settings during these acute, episodic changes, but research does not determine the exact degree of individual response.


Research Gaps and Unresolved Questions about Variquel

One key area is the variability in findings regarding long-term survival outcomes in HRS-AKI, as some findings were varied across different meta-analyses. Another area is the lack of clarity on the optimal treatment duration for acute variceal bleeding, as studies comparing a shorter course versus a longer course often report how symptoms evolved similarly across both groups. Comparative evidence is lacking in some contexts, and research is ongoing to better understand the role of Variquel alongside other available therapies.

Frequently Asked Questions (FAQ)

Common questions about Variquel (FAQ)

Q: Why is Variquel prescribed instead of other common treatments?

A: Variquel is a potent vasoconstrictor that selectively targets blood vessels in the splanchnic circulation (digestive organs). Official use is to help reduce high blood pressure in the portal venous system. This targeted action is utilized in acute situations, such as managing Hepatorenal Syndrome–Acute Kidney Injury (HRS-AKI) and acute bleeding from esophageal varices.


Q: How quickly should I expect to feel the effects of Variquel?

A: Variquel is administered directly into a vein as a slow injection to ensure immediate circulation and absorption. Official information does not provide a specific timeframe (e.g., minutes or hours) for when patients might notice subjective changes related to the medicine. The first clinical assessment of its measurable effectiveness on kidney function is scheduled on the fourth day of treatment.


Q: Is Variquel safe for long-term use?

A: The medicine is generally restricted to treatment courses lasting a maximum of 14 days. Its use is intended for acute clinical situations. Safety and effectiveness have not been established for use beyond this acute period, according to official prescribing information.


Q: What are the most commonly reported mild side effects of Variquel?

A: Official safety data indicates that other common effects include headaches and bradycardia (slow heart rate). Some side effects observed very frequently (10%), such as abdominal pain and diarrhea, may vary in severity. If you experience side effects, they should be discussed with the prescribing professional.


Q: Can Variquel affect your mood or energy levels?

A: While the official list of adverse reactions includes effects on several body systems, it does not explicitly list effects on mood or energy levels in the most common categories. However, any new or worsening symptoms should be discussed with the prescribing healthcare professional.


Q: What should I know about taking Variquel while pregnant or breastfeeding?

A: Variquel is strictly contraindicated (must not be used) in women who are pregnant. For nursing mothers, regulatory documents state that a risk to the child cannot be excluded. Therefore, a decision is necessary, managed by a physician, to either discontinue the medicine or discontinue breastfeeding.


Q: Why do some people say Variquel didn't work for them?

A: Official treatment protocols include a requirement to assess the medicine’s effectiveness on the fourth day of treatment. If kidney function has not improved sufficiently, the medicine should be discontinued. Official research indicates that variation in patient response is expected.


Q: What's the difference between Variquel and [Competitor Drug Name]?

A: Variquel is a synthetic prodrug that is converted in the body into an active substance called lypressin. This conversion helps provide a longer duration of physiological activity than the natural hormone. Its main function is a targeted tightening of blood vessels (vasoconstriction) in the digestive system.


Q: Does Variquel cause headaches or dizziness?

A: Yes, regulatory safety information indicates that headache is reported as a common side effect, occurring in 1% to 10% of patients. While dizziness is not listed in the common frequency categories, changes in blood pressure and circulation can sometimes cause related symptoms.


Q: Is it normal to feel a bit nauseous when starting Variquel?

A: Official prescribing information indicates that nausea is listed as a very common side effect, meaning it is frequently observed during treatment, occurring in 10% of patients.


Q: Can I take Variquel if I'm already taking a daily vitamin C supplement?

A: Official regulatory information focuses on documented interactions with specific classes of prescription medicines. It does not document specific drug-supplement interactions affecting how the body breaks down Variquel. It is important to discuss all supplements, including Vitamin C, with the prescribing healthcare professional.


Q: Is it better to take Variquel in the morning or at night?

A: The medicine is administered on a strict schedule of every six hours (q6h). Regulatory information does not specify a preferred time of day for the first dose or any subsequent dose, only the requirement for the continuous four-times-daily interval.


Q: Does Variquel interact with herbal supplements like St. John's Wort?

A: Official regulatory information states there are no documented restrictions concerning herbal products. However, caution is required with any medicine or supplement that could potentially affect the heart's rhythm or cause electrolyte changes.


Q: Will Variquel affect my ability to drive or operate machinery?

A: No specific studies on the medicine’s effects on driving or machine use have been performed. Because of the potential for side effects, patients should be cautious regarding activities that require alertness until they know how the medicine affects them.


Q: What happens if I accidentally take too much Variquel?

A: Official information regarding overdose indicates that taking too much Variquel may lead to a severe hypertensive crisis (dangerously high blood pressure) and bradycardia (a very slow heart rate). Overdose is managed by discontinuing the medicine and providing appropriate medical support to address these effects.


Q: How common are allergic reactions to Variquel?

A: Hypersensitivity (a severe allergic reaction) is listed in regulatory documents as an absolute contraindication, meaning the medicine must never be used in anyone with a known allergy to the active substance. The frequency of general allergic reactions, however, is not explicitly listed in the common frequency categories.


Q: Is Variquel suitable for people with sensitive stomachs?

A: The medicine frequently causes gastrointestinal side effects. Official safety data indicates that abdominal pain and diarrhea are both listed as very common adverse reactions, meaning they are observed in 10% of patients.


Q: What if I experience unusual anxiety while taking Variquel?

A: The medicine's official safety profile lists several nervous system effects, such as headache. Any significant or unusual new nervous system symptom, like anxiety, should be discussed with the prescribing healthcare professional.


Q: Can Variquel cause weight gain or loss?

A: The official label lists fluid overload as a common side effect. While this is not explicitly defined as weight gain, fluid retention can certainly lead to an increase in body mass. Explicit weight loss is not a documented adverse event in the common frequency categories.


Q: Is Variquel effective for preventing a condition from worsening?

A: Variquel is indicated for the treatment and reversal of acute conditions, specifically to improve kidney function in HRS-AKI or achieve initial control of acute bleeding. Its labeled use is primarily focused on treating an active, acute phase rather than routine prevention.


Q: How soon after starting Variquel should I see a doctor if I don't feel better?

A: The official treatment protocol builds in a clinical reassessment, often by the fourth day of therapy, to determine if kidney function is improving sufficiently. If the clinical response is insufficient, a doctor will decide whether to stop or adjust the medicine.


Q: What is the proper way to discontinue Variquel treatment?

A: The medicine is generally discontinued once the patient achieves a sustained improvement in kidney function, after a maximum of 14 days of therapy, or if the clinical response is insufficient after Day 4. The decision and process for discontinuing the medicine are determined and managed entirely by the treating physician based on the patient's clinical status.


Q: Does Variquel require a specific preparation before use?

A: If the medicine is supplied as a powder, it requires reconstitution (mixing) with a specific solution before administration. The solution must also be visually inspected for any particles or discoloration to ensure product integrity before use.


Q: Can Variquel be crushed or split for easier swallowing?

A: No. The medicine is an injectable solution that is administered directly into a vein. It is not available in a form that can be crushed, split, or swallowed, as its polypeptide structure requires the intravenous route for immediate and full therapeutic effect.


Q: Are there any known withdrawal symptoms if I stop Variquel suddenly?

A: Regulatory documents address how and when to stop the medicine, but they do not list or discuss specific physiological withdrawal or rebound effects upon sudden cessation. The decision to discontinue is based on clinical improvement.

How should Variquel be stored and disposed of?

Storage and Disposal of Variquel

Variquel solution must be stored in a refrigerator at the mandatory temperature range of mathbf2 C to mathbf8 C (36 F to 46 F) and must not be frozen. The product must be kept in its original outer carton to ensure it is protected from light and should not be used past the expiration date.

Handling and Safety

Requirement Rule
Child Safety Keep out of the sight and reach of children.
Product Integrity Inspect visually for particles and discoloration before use; do not use if discolored.

Disposal Requirements

Unused or expired Variquel must not be disposed of through household waste or wastewater. The medicine must be returned to a doctor or healthcare professional for proper handling, which ensures adherence to pharmaceutical waste regulations and protection of the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Variquel found in:

A-Z Index: